Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-3050, an FAP-Targeted Radioligand Therapy, in Patients with FAP-Expressing Advanced Solid Tumors

Phase 1IM-3050Positive

AI Analysis

Summary

Immunome announced the first patient dosed in a Phase 1 trial of IM-3050, an FAP-targeted radioligand therapy for patients with FAP-expressing advanced solid tumors.

Clinical Trial Data

Phase

Phase 1

Outcome Details

First patient dosed

Importance:5/10

Sentiment:

0.50

Phase 1Radioligand TherapyFAP-targetedOncologyTrial Initiation

Related Companies

$IMNM

Read the original article

Published by yahoo_finance on July 20, 2026 11:30 AM

Read Original